Biocept Inc  

(Public, NASDAQ:BIOC)   Watch this stock  
Find more results for BIOC
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.09 - 7.72
Open     -
Vol / Avg. 0.00/2.34M
Mkt cap 50.13M
P/E     -
Div/yield     -
EPS -2.78
Shares 17.90M
Beta     -
Inst. own 8%
Jun 8, 2015
Biocept Inc Roadshow - New York Add to calendar
May 12, 2015
Q1 2015 Biocept Inc Earnings Call
May 12, 2015
Q1 2015 Biocept Inc Earnings Release
Mar 11, 2015
Biocept Inc at ROTH Conference
Mar 9, 2015
Q4 2014 Biocept Inc Earnings Call
Mar 9, 2015
Q4 2014 Biocept Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -2533.82% -11891.81%
Operating margin -2433.74% -10398.68%
EBITD margin - -10210.40%
Return on average assets -110.92% -400.76%
Return on average equity -228.18% -
Employees 42 -
CDP Score - -


Suite 150, 5810 Nancy Ridge Drive
SAN DIEGO, CA 92121-2840
United States - Map
+1-858-3208200 (Phone)
+1-858-3208225 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Biocept, Inc.(Biocept) is a is a commercial-stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) tests utilizing a standard blood sample to improve the treatment that oncologists provide to their patients by providing better, more detailed information on the characteristics of their tumor. Additionally, it offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. The Company’s focus is to promote its unique technology (CEE- cell enrichment and extraction) and family of laboratory tests (OncoCEE) to the Oncology Community. Biocept provides products and services to detect and analyze these rare cells in order to provide information that physicians can use to make treatment decisions.

Officers and directors

Michael W. Nall President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
William G. Kachioff Chief Financial Officer, Senior Vice President - Finance
Age: 49
Bio & Compensation  - Reuters
Lyle J. Arnold Ph. D. Senior Vice President - Research & Development, Chief Scientific Officer
Age: 68
Bio & Compensation  - Reuters
Veena Singh M.D. Senior Vice President, Senior Medical Director
Age: 40
Bio & Compensation  - Reuters
Raaj Trivedi Vice President - Commercial Operations
Age: 42
Bio & Compensation  - Reuters
David F. Hale Non-Executive Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
M. Faye Wilson CPA, Lead Independent Director
Age: 77
Bio & Compensation  - Reuters
Marsha A. Chandler Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Bruce E. Gerhardt CPA Independent Director
Age: 63
Bio & Compensation  - Reuters
Bruce A. Huebner Independent Director
Age: 64
Bio & Compensation  - Reuters